comparemela.com
  1. Home
  2. Live Updates
  3. Anthos Therapeutics Inc - Breaking News

Latest Breaking News On - Anthos therapeutics inc - Page 1 : comparemela.com

Anthos Therapeutics Announces Appointment of Bill Meury as CEO

Anthos Therapeutics Announces Appointment of Bill Meury as CEO
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJohn glasspoolNicholas galakatosBristol myers squibbThromb haemostDavid gailaniAndras gruberColl cardiolAbelacimab atrial fibrillation af programUniversity of marylandBranded pharmaceuticals for actavisStudy groupProgram in cancer associated thrombosisAnthos therapeutics incGlobal head of blackstone life sciences

Analyst Assess Implications of Bristol Myers Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence - Bristol-Myers Squibb (NYSE:BMY)

Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF) 

Bayer agbayrybayzfstoppedWilliam blairBristol myers squibb companyBristol myerBristol myersPhoto via companyPfizer incAnthos therapeutics incBristol myers squibbMarket perform

Anthos Therapeutics Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov 12, 2023

United statesUnited kingdomColl cardiolThromb haemostDan bloomfieldAnthos therapeutics incAmerican heart associationHarvard medical schoolDrug administrationProgram in cancer associated thrombosisBlackstone life sciencesBroad instituteCenters for diseasePrimary endpointClinically relevant non major bleeding comparedAtrial fibrillation

Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions

Study participants may transition from the rivaroxaban arm to abelacimab in an extension study 

United statesJohn glasspoolStudy groupData monitoring committeeBroad instituteDrug administrationAmerican heart association scientific sessionsBlackstone life sciencesHarvard medical schoolAnthos therapeutics incPennsylvania convention centerAnthos therapeuticsLate breakingPrincipal investigator christianGeneral cardiologySenior investigator

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC

Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC 

United statesLewis dexterThromb haemostMarcs sabatineDan bloomfieldColl cardiolHarvard medical schoolData monitoring committeeBlackstone life sciencesStudy groupNational blood clot allianceAnthos therapeutics incAnthos therapeuticsDistinguished chairCardiovascular medicineMyocardial infarction

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.